PRECISION BIOSCIENCES INC (DTIL) Stock Research
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Latest price: 6.24 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Germano Geno J | buy | 2026-09-25 | 16384.52 |
| Brown Melinda | buy | 2026-09-25 | 7116.45 |
| Kelly John Alexander | sell | 2026-02-18 | 31292.16 |
| Amoroso Michael | sell | 2026-02-18 | 78946.56 |
| SMITH J. JEFFERSON | sell | 2026-02-18 | 18912 |
| Scimeca Dario | sell | 2026-02-18 | 18912 |
| Kelly John Alexander | sell | 2026-01-21 | 61308.39 |
| SMITH J. JEFFERSON | sell | 2026-01-21 | 41106 |
| Scimeca Dario | sell | 2026-01-21 | 35681.62 |
| Amoroso Michael | sell | 2026-01-22 | 145111.83 |